Shanghai Shenqi Medical Technology Co., Ltd.

Shenqi Medical is an innovative medical device enterprise integrating R&D, production, and sales, with product portfolio covering cardiovascular intervention, structural heart disease, peripheral vascular intervention, and neurovascular intervention. The company also has an associated enterprise, Beijing Hartcare Medical Technology Co., Ltd. ("Hartcare"). Currently, it has 6 marketed products and 15 products under development, all independently developed with comprehensive independent intellectual property rights. Among them, the swide® Qiji® drug-coated coronary balloon catheter was approved by the National Medical Products Administration (NMPA) as a Class III medical device in December 2019 and has entered over 1,100 hospitals nationwide; the peripheral vascular intervention product SQ-WindRider® Qiyi® detachable fiber-wound coil embolization system obtained NMPA Class III medical device registration in January 2022; and the SQ-Kyrin® Shenqi Qilin® transcatheter mitral valve clip and steerable guide catheter entered the national green channel for innovative medical device registration in August 2021. As a medical enterprise rooted in China, Shenqi Medical adheres to the philosophy of "Innovation · Heart Protection" and is committed to the mission of "better meeting the rapidly growing medical and health needs of the Chinese market," providing comprehensive solutions in the field of cardiovascular disease treatment through the R&D and innovation of high-quality cardiac and vascular interventional products, benefiting more Chinese patients.